PARP Inhibitors in Ovarian Cancer

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.